Details

Autor(en) / Beteiligte

• Gutierrez, Andres A

Titel

Embracing the Promise of Oncolytic Virus Immunotherapy

Ist Teil von

• Drug Discovery & Development, 2017-09

Ort / Verlag

Rockaway: Advantage Business Media

Erscheinungsjahr

2017

Beschreibungen/Notizen

• Most recently he has held progressively senior clinical development positions designing and implementing both early and later-stage oncology clinical studies at a range of U.S. and European companies including Sellas Life Sciences Group, Bristol-Myers Squibb, Sunesis Pharmaceuticals Inc., Biomarin Pharmaceutical Inc., Proteolix, and Oculus Innovative Sciences. Oncolytics' clinical development program emphasizes three pillars: chemotherapy combinations to trigger selective tumor lysis; immuno-therapy combinations to produce adaptive immune responses; and immune modulator (IMiD) combinations to facilitate innate immune responses.